Pharma Has Limited Legal Options If Vaccine Patents Waived
- Issue faces thorny negotiations at World Trade Organization
- Legal recourse to recover costs gets tricky outside the U.S.
This article is for subscribers only.
A potential World Trade Organization waiver of patent and trade secret protections for Covid-19 vaccines would leave pharmaceutical companies with limited legal avenues to recover costs.
The U.S. on Wednesday expressed support for a temporary waiver, sending shares in several vaccine makers down the next day. The issue now faces thorny negotiations at the WTO, where several members, including Germany, have opposed efforts to skirt intellectual property rights. They say it would only complicate production and make companies less likely to respond in the future.